San Antonio, TX. December 7, 2023: Etira is pleased to present the data with its lead compound ERX-315 that cause catastrophic levels of ER stress, resulting in breast cancer cell death, and that can successfully function against multiple…
https://etira.life/wp-content/uploads/2024/02/image-1-scaled.jpeg19202560Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2023-12-07 11:10:162026-01-02 12:18:37ERX-315 introduced at SABCS 2023
Dallas, TX. October 2, 2023: Etira is pleased to note the independent validation of LIPA as a molecular target in TNBC in a preprint in biorxiv from Dr. Esser’s group in Dusseldorf, Germany.
The authors conclude that LIPA-activity is a novel…
https://etira.life/wp-content/uploads/2023/10/image.png5901000Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2023-10-02 11:48:592026-01-02 12:17:04Independent validation of LIPA as a molecular target in TNBC
Dallas, Texas. June 1, 2023:
One year after its online publication, we are pleased to note that our manuscript titled “Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid…
https://etira.life/wp-content/uploads/2023/06/nature-cancer-thumbnail.jpg661648Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2023-06-01 17:50:412023-11-30 12:45:37One year later, highest almetric score for any paper published in Nature Cancer!
Dallas, Texas. April 18, 2023:
Etira is pleased to announce that multiple abstracts related to their licensed products showed encouraging preclinical activity in metastatic breast cancer and ovarian cancer. The data, presented…
https://etira.life/wp-content/uploads/2023/04/Annual-Meet-Feature-Image.jpg661648Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2023-04-18 16:49:332026-01-02 12:12:57Positive preclinical data presented at AACR 2023
Dallas, Texas. April 17, 2023:We are excited to congratulate one of our founders, Dr. Ratna Vadlamudi, Professor and Vice Chair for Research, Division of Reproductive Research, Department of Obstetrics & Gynecology, Long School of…
https://etira.life/wp-content/uploads/2023/04/UT-Health-Feature-Health.jpg661648Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2023-04-17 16:42:112024-02-13 11:16:08Etira founder Dr. Ratna Vadlamudi honored with the prestigious 2023 Distinguished Research Scholar Award
Dallas, Texas. December 9, 2022:
Etira is pleased to report the abstract related to ERX-41 validating its activity in Triple negative breast cancer was presented at the San Antonio Breast Cancer Symposium (SABCS). The SABCS is one of the world's…
https://etira.life/wp-content/uploads/2022/12/San-Antonio-Breast-Cancer-Thumbnail-1.jpg661648Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2022-12-09 15:45:172023-11-30 12:49:50Preclinical data on TNBC presented at SABCS 2022
Dallas, Texas. October 31, 2022. We are pleased to share two news articles from Dallas that describe how our brilliant chemist and founder, Dr. Jung-Mo Ahn discovered ERX-41. In his words, Dr. Ahn describes the discovery of ERX-41 as “It’s…
https://etira.life/wp-content/uploads/2022/10/Annual-Meet-Feature-Image.jpg661648Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2022-10-31 18:34:572026-01-02 11:33:41Etira founder Dr. Jung-Mo Ahn highlighted in local press
Dallas, Texas. October 10, 2022:etiraRx's lead drug candidate, ERX-41 has been highlighted in the most recent edition of Oncology Times. In an article entitled "Molecule Targets Vulnerability in Triple-Negative Breast Cancer," Dibash…
https://etira.life/wp-content/uploads/2022/10/Oncology-thumbnail.jpg661648Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2022-10-10 14:45:172026-01-02 11:31:23Oncology Times Highlights ERX-41
Dallas Texas, September 23, 2022. We are pleased to announce that Etira has been selected as a 2022 BioNTX rising star.
The BioNTX iC³ Life Science Summit is a two-day conference, held on September 22-23, 2022 that serves as a forum where…
https://etira.life/wp-content/uploads/2022/09/bio-ntx.jpg661648Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2022-09-23 18:41:022023-11-30 12:57:48Etira selected as a 2022 BioNTX rising star
Dallas, Texas. July 7, 2022:
On the cover of the July 2022 issue of Nature cancer is an image of the endoplasmic reticulum within a cell. Image courtesy of Dr. Andrew S. Moore, Janelia Research Campus. Cover Design by Allen Beattie. Highlighted…
https://etira.life/wp-content/uploads/2023/06/nature-cancer-cover-1.jpg743556Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2022-07-10 15:30:512023-11-30 12:57:25ERX-41 Paper image selected for Nature Cancer cover
Patients must be at least 18 years of age at the time of signing the informed consent.
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
Patients must have histologically or cytologically confirmed solid tumor, primarily including but not limited to breast, ovarian, pancreatic, endometrial, and hepatocellular carcinoma, that is advanced unresectable and/or metastatic disease for whom standard therapies do not exist or are no longer effective
Patients must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Adequate baseline organ function and hematologic function
Life expectancy >3 months
Exclusion criteria
Systemic anti-cancer therapy within 4 weeks of first dose of study drug
Major surgery (as defined by the Investigator) within 4 weeks of first dose of study drug.
Uncontrolled intercurrent illnesses
Known history of LIPA deficiency, such as Wolman disease or Cholesterol ester storage disease.
ERX-315 introduced at SABCS 2023
NewsIndependent validation of LIPA as a molecular target in TNBC
NewsOne year later, highest almetric score for any paper published in Nature Cancer!
NewsPositive preclinical data presented at AACR 2023
NewsEtira founder Dr. Ratna Vadlamudi honored with the prestigious 2023 Distinguished Research Scholar Award
NewsPreclinical data on TNBC presented at SABCS 2022
NewsEtira founder Dr. Jung-Mo Ahn highlighted in local press
NewsOncology Times Highlights ERX-41
NewsEtira selected as a 2022 BioNTX rising star
NewsERX-41 Paper image selected for Nature Cancer cover
News